Related Experiment Video
Updated: Jan 2, 2026
06:18
A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
Published on: March 3, 2023
1.7K
Evaluation of a modified vancomycin nomogram for obese adults
Nathan Batchelder1, Carrie Faith Lutheran2, Jeremy Frens3
1Department of Pharmacy, Moses H. Cone Memorial Hospital, 1121 N. Church Street, Greensboro, NC, 27401, USA. nathan.batchelder@conehealth.com.
European Journal of Clinical Pharmacology
|December 14, 2019
Summary
A modified vancomycin dosing nomogram improved therapeutic drug levels in obese adults. This approach reduced both under- and over-dosing, offering a better tool for vancomycin administration in this patient population.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Obesity Medicine
Background:
- Vancomycin is a critical antibiotic for treating serious Gram-positive infections.
- Obese patients present unique challenges in achieving therapeutic vancomycin concentrations due to altered pharmacokinetics.
- Accurate dosing is essential to maximize efficacy and minimize toxicity.
Purpose of the Study:
- To compare the efficacy of an original vancomycin dosing nomogram versus a modified nomogram in achieving therapeutic trough levels in obese adults.
- To evaluate the impact of a modified nomogram on sub-therapeutic and supra-therapeutic vancomycin concentrations.
Main Methods:
- A comparative study involving obese adults (100-299 kg) using either an original or modified vancomycin nomogram.
- Primary endpoint: percentage of sub-therapeutic, therapeutic, and supra-therapeutic vancomycin trough concentrations.
- Exclusion criteria: end-stage renal disease or continuous renal replacement therapy.
Main Results:
- Therapeutic vancomycin trough levels were achieved in 50% (Phase I) versus 66% (Phase II) of patients.
- The modified nomogram (Phase II) significantly reduced the incidence of sub-therapeutic and supra-therapeutic levels (p=0.013).
- Subgroup analysis showed improved therapeutic levels in patients with creatinine clearance 60-90 mL/min (p=0.001).
Conclusions:
- The modified vancomycin nomogram significantly improved therapeutic trough concentrations in obese adults.
- This revised nomogram effectively reduced rates of both under- and over-dosing.
- The modified nomogram is a valuable tool for optimizing initial vancomycin dosing in obese patients.
Related Concept Videos
01:21Drug Dosing: Obese Patients
172
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
172
01:23Dosage Regimen Designs: Nomograms and Tabulations
132
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
132
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
135
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
135
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
200
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
200
00:56One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
309
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
309
01:15Drug Dosing: Geriatric Patients
187
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
187